FDA Recall Lamotrigine

The last Recall Enforcement Report for Lamotrigine with NDC 51672-4132 was initiated on 12-20-2019 as a Class I recall due to cross contamination; lamotrigine tablets 100 mg usp was contaminated with enalapril maleate. The latest recall number for this product is D-0833-2020 and the recall is currently terminated as of 02-23-2024 .

Recall Number D-0833-2020

Field Name	Field Value
Event ID	84645 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number	D-0833-2020 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification	Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern	Nationwide in the U.S. and Puerto Rico. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description	Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4131-1.
Reason For Recall	Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate. What is the Reason for Recall? Information describing how the product is defective.
Product Quantity	Product Quantity The amount of product subject to recall.
Voluntary Mandated	Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date	02-19-2020
Recall Initiation Date	12-20-2019 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall.
Termination Date	02-23-2024 What is the Date Terminated? The date that FDA terminated the recall.
Initial Firm Notification	Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type	Drugs
Recalling Firm	Taro Pharmaceuticals U.S.A., Inc.
Code Info	Lot #: 331771, Exp. June 2021 Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages	51672-4130-6; 51672-4130-4; 51672-4130-1; 51672-4130-3; 51672-4130-0; 51672-4131-6; 51672-4131-4; 51672-4131-1; 51672-4131-3; 51672-4131-0; 51672-4132-6; 51672-4132-4; 51672-4132-1; 51672-4132-2; 51672-4132-3; 51672-4132-0; 51672-4133-6; 51672-4133-4; 51672-4133-1; 51672-4133-2; 51672-4133-3; 51672-4133-0
Status	Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
	View Recall Report

What is the Enforcement Report?

All drug recalls are monitored by the Food and Drug Administration (FDA) and are included in the Enforcement Report once they are properly classified. The FDA will determine if a firm's removal or correction actions of a marked product meet the requirements to be considered a "recall". The FDA will also determine the public hazard assessment and a recall classification will be published in the Enforcement Report.